Please login to the form below

Not currently logged in

Bayer’s Nexavar recommended for thyroid cancer in EU

CHMP backs extra indication for cancer drug
Bayer Nexavar sorafenib

An extra cancer indication for Bayer's Nexavar was among the latest set of drug recommendations from the European Medicines Agency (EMA).

Although the Agency's Committee for Medicinal Products for Human Use (CHMP) this month backed just one new drug in the form of GlaxoSmithKline's skin cancer drug Mekinist (trametinib), it recommended seven licence extensions for already-approved drugs, including the use of Nexavar (sorafenib) in people with advanced thyroid cancer.

If sanctioned by the European Commission the indication would add to Nexavar's existing recommendations in the liver and kidney cancer.

The latest indication specifically covers the use of Nexavar to treat advanced forms of differentiated thyroid cancer, the third most common type of thyroid cancer. Around 37,000 new cases of thyroid cancer were reported in 2012 and over 3,600 people died from the disease.

There are few current treatment options for the cancer, which is generally treated with radioactive iodine, surgery and therapy to suppress thyroid-stimulating hormone.

As such, Nexavar's recommendation could be an important step in the field, and covers its use in patients who no longer respond to treatment with radioactive iodine.

Pradaxa in DVT and PE

Meanwhile, competition among the new generation of anticoagulants continued to heat up as Boehringer Ingelheim received a new recommendation for the use of Pradaxa (dabigatran etexilate) in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.

This adds to its existing indications in the prevention of stroke in patients with non-valvular atrial fibrillation and in the prevention of blood clots in adults who have an operation to replace a hip or knee.

Assuming the CHMP recommendation translates into full approval for the PE and DVT indication it would put Pradaxa in line with rival Xarelto from Bayer and a step ahead of Eliquis from Pfizer/Bristol-Myers Squibb, each of which is also looking to establish itself as a safer, more convenient alternative to warfarin.

HPV vaccines

The remaining CHMP opinions this month included updated indications for two vaccines for human papillomavirus vaccine – a cause of cervical cancer.

Both Sanofi's Gardasil and Merck & Co's Silgard are recommended to have their indication revised to prevent the following in children as young as nine: premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic HPV types. They both also have a genital warts indication.

Other new indications

Elsewhere, Janssen's antipsychotic Invega (paliperidone) was backed to expand its use to include schizophrenia patients as young as 15 and the CHMP recommended revised indications for Novartis' Gilenya (fingolimod) and Amgen's Prolia (denosumab).

Article by
Thomas Meek

28th April 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...